MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 581649 | Name: Dibekacin sulfate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dibekacin sulfate is an analog of KANAMYCIN with antitubercular as well as broad-spectrum antimicrobial properties.

Chemical Structure

Dibekacin sulfate
CAS#58580-55-5 (sulfate)

Theoretical Analysis

MedKoo Cat#: 581649

Name: Dibekacin sulfate

CAS#: 58580-55-5 (sulfate)

Chemical Formula: C18H37N5O12S2

Exact Mass: 547.2170

Molecular Weight: 547.58

Elemental Analysis: C, 39.48; H, 6.81; N, 12.79; O, 35.06; S, 5.85

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
34493-98-6 (free base) 58580-55-5 (sulfate)
Synonym
Dibekacin sulfate; Debecacin sulfate; EINECS 261-341-0; Orbicin; Panimycin.
IUPAC/Chemical Name
(2S,3S,4S,5S,6R)-4-amino-2-(((1S,2S,3R,4S,6R)-4,6-diamino-3-(((2R,3R,6R)-3-amino-6-(aminomethyl)tetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol, sulfate salt
InChi Key
GXKUKBCVZHBTJW-PMAQWHKESA-L
InChi Code
InChI=1S/C18H37N5O8.H2O4S/c19-4-6-1-2-7(20)17(28-6)30-15-8(21)3-9(22)16(14(15)27)31-18-13(26)11(23)12(25)10(5-24)29-18;1-5(2,3)4/h6-18,24-27H,1-5,19-23H2;(H2,1,2,3,4)/p-2/t6-,7-,8+,9-,10-,11+,12-,13+,14+,15-,16+,17-,18-;/m1./s1
SMILES Code
O1[C@@H]([C@H]([C@H](N)[C@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@@H]([C@H](C[C@H]1N)N)O[C@@H]1[C@H](N)CC[C@H](CN)O1)O)CO.S(=O)(=O)([O-])[O-]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 547.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhang S, Chen T, Jia J, Guo L, Zhang H, Li C, Qiao R. Establishment of a highly efficient conjugation protocol for Streptomyces kanamyceticus ATCC12853. Microbiologyopen. 2018 Nov 17:e747. doi: 10.1002/mbo3.747. [Epub ahead of print] PubMed PMID: 30449069. 2: Liu L, Li Z, Liu X, Guo S, Guo L, Liu X. Bacterial distribution, changes of drug susceptibility and clinical characteristics in patients with diabetic foot infection. Exp Ther Med. 2018 Oct;16(4):3094-3098. doi: 10.3892/etm.2018.6530. Epub 2018 Jul 26. PubMed PMID: 30214532; PubMed Central PMCID: PMC6125979. 3: Ohtsuru T, Morita Y, Murata Y, Munakata Y, Itoh M, Kato Y, Okazaki K. Custom-made, antibiotic-loaded, acrylic cement spacers using a dental silicone template for treatment of infected hip prostheses. Eur J Orthop Surg Traumatol. 2018 May;28(4):615-620. doi: 10.1007/s00590-017-2117-3. Epub 2018 Jan 13. PubMed PMID: 29332203. 4: Uechi K, Tada T, Shimada K, Nakasone I, Sonozaki T, Kirikae T, Fujita J. Emergence of ArmA, a 16S rRNA methylase in highly aminoglycoside-resistant clinical isolates of Klebsiella pneumoniae and Klebsiella oxytoca in Okinawa, Japan. J Infect Chemother. 2018 Jan;24(1):68-70. doi: 10.1016/j.jiac.2017.09.006. Epub 2017 Oct 21. PubMed PMID: 29066218. 5: Rominski A, Selchow P, Becker K, Brülle JK, Dal Molin M, Sander P. Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes. J Antimicrob Chemother. 2017 Aug 1;72(8):2191-2200. doi: 10.1093/jac/dkx125. PubMed PMID: 28486671. 6: Kaku N, Morinaga Y, Takeda K, Kosai K, Uno N, Hasegawa H, Miyazaki T, Izumikawa K, Mukae H, Yanagihara K. Efficacy and pharmacokinetics of ME1100, a novel optimized formulation of arbekacin for inhalation, compared with amikacin in a murine model of ventilator-associated pneumonia caused by Pseudomonas aeruginosa. J Antimicrob Chemother. 2017 Apr 1;72(4):1123-1128. doi: 10.1093/jac/dkw517. PubMed PMID: 27999047. 7: Nakamoto S, Goda N, Hayabuchi T, Tamaki H, Ishida A, Suzuki A, Nakano K, Yui S, Katsumata Y, Yamagami Y, Burioka N, Chikumi H, Shimizu E. Properties of Achromobacter xylosoxidans highly resistant to aminoglycoside antibiotics. Jpn J Antibiot. 2016 Apr;69(2):113-8. PubMed PMID: 27544979. 8: Suga T, Shiina M, Asami Y, Iwatsuki M, Yamamoto T, Nonaka K, Masuma R, Matsui H, Hanaki H, Iwamoto S, Onodera H, Shiomi K, Ōmura S. Paraphaeosphaeride D and berkleasmin F, new circumventors of arbekacin resistance in MRSA, produced by Paraphaeosphaeria sp. TR-022. J Antibiot (Tokyo). 2016 Aug;69(8):605-10. doi: 10.1038/ja.2016.70. Epub 2016 Jun 22. PubMed PMID: 27328869. 9: Hagihara M, Kato H, Hamada Y, Hirai J, Sakanashi D, Suematsu H, Nishiyama N, Koizumi Y, Yamagishi Y, Matsuura K, Mikamo H. Population pharmacokinetics of arbekacin in different infectious disease settings and evaluation of dosing regimens. J Infect Chemother. 2016 Jul;22(7):436-43. doi: 10.1016/j.jiac.2016.03.008. Epub 2016 May 31. PubMed PMID: 27260679. 10: Takeshima Y. [Genetic Diagnosis and Molecular Therapies for Duchenne Muscular Dystrophy]. Rinsho Byori. 2015 Oct;63(10):1194-201. Review. Japanese. PubMed PMID: 26897856. 11: Baek YS, Jeon J, Ahn JW, Song HJ. Antimicrobial resistance of Staphylococcus aureus isolated from skin infections and its implications in various clinical conditions in Korea. Int J Dermatol. 2016 Apr;55(4):e191-7. doi: 10.1111/ijd.13046. Epub 2016 Feb 19. PubMed PMID: 26892888. 12: Miura K, Nakagawa M, Takahashi H, Uchino Y, Kodaira H, Iriyama N, Sakagami M, Ohtake S, Kobayashi S, Hojo A, Kurita D, Kobayashi Y, Kusuda M, Hirabayashi Y, Hatta Y, Takei M. Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies. Int J Hematol. 2016 Mar;103(3):334-40. doi: 10.1007/s12185-015-1926-6. Epub 2015 Dec 29. PubMed PMID: 26715149. 13: Kimura Y, Morinaga Y, Akamatsu N, Matsuda J, Yamaryo T, Kawakami K, Matsuo H, Kosai K, Uno N, Hasegawa H, Yanagihara K. Antimicrobial susceptibility and molecular characteristics of methicillin-resistant Staphylococcus aureus in a Japanese secondary care facility. J Infect Chemother. 2016 Jan;22(1):14-8. doi: 10.1016/j.jiac.2015.08.011. Epub 2015 Nov 24. PubMed PMID: 26617349. 14: McGann P, Chahine S, Okafor D, Ong AC, Maybank R, Kwak YI, Wilson K, Zapor M, Lesho E, Hinkle M. Detecting 16S rRNA Methyltransferases in Enterobacteriaceae by Use of Arbekacin. J Clin Microbiol. 2016 Jan;54(1):208-11. doi: 10.1128/JCM.02642-15. Epub 2015 Nov 4. PubMed PMID: 26537447; PubMed Central PMCID: PMC4702724. 15: Sato K. External ocular infections due to methicillin-resistant Staphylococcus aureus and medical history. Can J Ophthalmol. 2015 Oct;50(5):e97-9. doi: 10.1016/j.jcjo.2015.05.006. Epub 2015 Jul 23. PubMed PMID: 26455994. 16: Galimand M, Fishovitz J, Lambert T, Barbe V, Zajicek J, Mobashery S, Courvalin P. AAC(3)-XI, a new aminoglycoside 3-N-acetyltransferase from Corynebacterium striatum. Antimicrob Agents Chemother. 2015 Sep;59(9):5647-53. doi: 10.1128/AAC.01203-15. Epub 2015 Jul 6. PubMed PMID: 26149994; PubMed Central PMCID: PMC4538504. 17: Hwang JH, Lee JH, Hwang JH, Chung KM, Lee EJ, Yoon YJ, Moon MK, Kim JS, Won KS, Lee CS. Comparison of Arbekacin and Vancomycin in Treatment of Chronic Suppurative Otitis Media by Methicillin Resistant Staphylococcus aureus. J Korean Med Sci. 2015 Jun;30(6):688-93. doi: 10.3346/jkms.2015.30.6.688. Epub 2015 May 13. PubMed PMID: 26028918; PubMed Central PMCID: PMC4444466. 18: Sasaki K, Kobayashi Y, Kurihara T, Yamashita Y, Takahashi Y, Miyake T, Akamatsu Y. Synthesis and antibacterial activity of 4″ or 6″-alkanoylamino derivatives of arbekacin. J Antibiot (Tokyo). 2015 Dec;68(12):741-7. doi: 10.1038/ja.2015.61. Epub 2015 May 20. PubMed PMID: 25990952. 19: Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia. Antimicrob Agents Chemother. 2015;59(6):3263-70. doi: 10.1128/AAC.04839-14. Epub 2015 Mar 23. PubMed PMID: 25801559; PubMed Central PMCID: PMC4432132. 20: Umemura E, Sakamoto Y, Takahashi Y, Miyake T. Synthesis and antibacterial activity of 1-N-[(S)-ω-amino-2-hydroxyalkyl] derivatives of dibekacin, 5-deoxydibekacin, 3'-deoxykanamycin A and gentamicin B. J Antibiot (Tokyo). 2015 Jun;68(6):421-3. doi: 10.1038/ja.2015.6. Epub 2015 Feb 25. PubMed PMID: 25712399.

View History

Dihydrojasmone

Dihydrojasmone

Featured